All these data demonstrated that our developed degradation system could degrade EGFR mutants and inhibit HDAC activity in both gefitinib‐resistant and osimertinib‐resistant lung tumor tissues and exhibited potent in vivo anti‐cancer effect with good safety. Here, HDAC9 is linked to cancer.